

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 February 2003 (06.02.2003)

PCT

(10) International Publication Number
WO 2003/010283 A3

(51) International Patent Classification⁷: **C07H 21/00**,
C12Q 1/68

(21) International Application Number:
PCT/US2002/022629

(22) International Filing Date: 15 July 2002 (15.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/915,485 25 July 2001 (25.07.2001) US

(71) Applicant (for all designated States except US): **ISIS
PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday
Avenue, Carlsbad, Ca California 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MONIA, Brett, P.**
[US/US]; 2306 Casa Hermosa Court, Encinitas, CA 92024
(US). **WYATT, Jacqueline, R.** [US/US]; 1065 Hymettus
Avenue, Encinitas, CA 92024 (US).

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
3 February 2005

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ANTISENSE MODULATION OF PKA REGULATORY SUBUNIT RII BETA EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PKA regulatory subunit RII beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PKA regulatory subunit RII beta. Methods of using these compounds for modulation of PKA regulatory subunit RII beta expression and for treatment of diseases associated with expression of PKA regulatory subunit RII beta are provided.



WO 2003/010283 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/22629

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/00; C12Q1/68

US CL : 514/44; 435/6, 325, 375; 536/23.1, 24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 435/6, 325, 375; 536/23.1, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Biosis, Medline, CA, Embase, SciSearch, USPTO Databases**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PAOLILLO M. et al. The type and the localization of camp-dependent protein kinase regulate transmission of camp signals to the nucleus in cortical and cerebellar granule cells. J. Biol. Chem. Vol 274, No. 10 pages 6546-6552	1, 2
---		-----
Y		1, 2, 4-20
X	TORTORA, G et al. An antisense oligodeoxynucleotide targeted against the type II regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without effecting phorbol ester effects. Proc. Natl. Acad. Sci. 1990, Vol 87. pages 705-708	1, 2
---		-----
Y		1, 2, 4-20
Y	US 5,801,154 (BARACCHINI et al) 01 September 1998 (01.09.1998)	1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

24 February 2003 (24.02.2003)

Date of mailing of the international search report

14 DEC 2004

Name and mailing address of the ISA/US


Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

James Douglas Schultz

Telephone No. 703-308-0196



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/22629

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1-20 as they pertain to SEQ ID NOS: 12, 33, and 45
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☒

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Claim 3 specifically claims SEQ ID NOS: 12-14, 16-32, 35, 38-40, 42, 45, 47-49, 52-54, 56-59, 62-66, 70-76, 79, 81-83, which are place into groups 1-52 respectively.

This international searching authority considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2, and 13.3) for the reasons indicated below:

According to the guidelines in Section (f)(i)(a) of Annex B of the PCT Administrative Instructions, the special technical feature as defined by PCT Rule 13.2 shall be considered to be met when all the alternatives of a Markush-group are of similar nature. For chemical alternatives, such as the claimed sequences, the Markush group shall be regarded as being of similar nature when

- (A) all alternatives have a common property or activity and
- (B)(1) a common structure is present, i.e., a significant structure is shared by all of the alternatives or
- (B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to an art recognized class of compounds in the art to which the invention pertains.

The instant sequences are considered to be each separate inventions for the following reasons:

The sequences do not meet the criteria of (A), common property or activity. Each sequence is unique, and each behaves in a different way in the context of the claimed invention. As demonstrated in Tables 1 and 2 of the specification, each sequence confers a different level of inhibition, and each member of the class cannot be substituted, one for the other, with the expectation that the same intended result would be achieved.

Further, the sequences do not meet the criteria of (B)(1), as they do not share, one with another, a common core structure, as each sequence is unique. Accordingly, unity of invention between the antisense sequences is lacking and each sequence claimed is considered to constitute a special technical feature.